News Release

Mount Sinai showcases breast cancer research at the 2025 San Antonio Breast Cancer Symposium

Meeting Announcement

The Mount Sinai Hospital / Mount Sinai School of Medicine

 

New York, NY (December 8, 2025) – Researchers and clinicians from the Icahn School of Medicine at Mount Sinai will present new discoveries in breast cancer biology, treatment, and real-world patient outcomes at the 2025 San Antonio Breast Cancer Symposium (SABCS), Tuesday-Friday, December 9-12, in San Antonio, Texas.

SABCS is one of the world’s leading conferences dedicated to breast cancer research and clinical advances, bringing together global experts to highlight the newest insights that may shape the future of care. Mount Sinai’s contributions this year span artificial intelligence, triple-negative breast cancer, geriatric oncology, and novel therapeutic approaches.

Below is a selection of Mount Sinai’s presentations at SABCS 2025:

Oral Session:

Multimodal artificial intelligence (AI) models integrating image, clinical, and molecular data for predicting early and late breast cancer recurrence in TAILORx

Joseph Sparano, MD

Wednesday December 10, General Session 1, 9:30 am-noon CST

https://sabcs.org/events/general-session-1/

 

Posters:

Abstract: 2137

A novel therapeutic targeting triple negative breast cancer brain metastases

Hanna Irie, MD, PhD

 

Abstract: 811

Tolerability of the KEYNOTE-522 regimen in a diverse real-world cohort of patients with early triple negative breast cancer (TNBC)
Justine M. Anderson, MD (Clinical Fellow, Hematology and Medical Oncology); Rima Patel, MD, is senior author

 

Abstract: 865

Evaluating real world pathologic complete response (pCR) rates at an urban center following the KEYNOTE-522 regimen for early-stage TNBC

Justine M. Anderson, MD (Clinical Fellow, Hematology and Medical Oncology); Rima Patel, MD, is senior author

 

Abstract: 869

Evaluating the tolerability of the combination of adjuvant pembrolizumab and capecitabine in a diverse real-world cohort of patients with early-stage TNBC

Prathyusha Pandu, MD (Internal Medicine resident); Amy Tiersten, MD, is senior author

 

Presentation: #PS4-07-26

Safety and efficacy of neoadjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) and pembrolizumab in older adults with early triple negative breast cancer (TNBC)

Rima Patel, MD

 

Presentation: #PS5-09-21

Feasibility of Clinical Nurse-Initiated Geriatric Assessments in Breast Medical Oncology Clinic: A Pilot Program

Rima Patel, MD

For a full list of presentations or to learn more about the 2025 San Antonio Breast Cancer Symposium, visit https://sabcs.org/.

 

###

About the Icahn School of Medicine at Mount Sinai 

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population. 

 

The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 560 postdoctoral research fellows. 

 

Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges.  More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.

------------------------------------------------------- 

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.  

 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.